Literature DB >> 36053518

PD-1 Blockade in Mismatch Repair-Deficient Rectal Cancer. Reply.

Andrea Cercek1, Luis A Diaz1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 36053518     DOI： 10.1056/NEJMc2209706

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   176.079


× No keyword cloud information.
  2 in total

1.  A Phase I-II multicenter trial with Avelumab plus autologous dendritic cell vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer patients; GEMCAD 1602 study.

Authors:  Marta Español-Rego; Carlos Fernández-Martos; Elena Elez; Carles Foguet; Leire Pedrosa; Nuria Rodríguez; Ana Ruiz-Casado; Estela Pineda; Joan Cid; Raquel Cabezón; Helena Oliveres; Miquel Lozano; Angels Ginés; Angeles García-Criado; Juan Ramon Ayuso; Mario Pagés; Miriam Cuatrecasas; Ferràn Torres; Timothy Thomson; Marta Cascante; Daniel Benítez-Ribas; Joan Maurel
Journal:  Cancer Immunol Immunother       Date:  2022-09-09       Impact factor: 6.630

Review 2.  Immunotherapy for GI Malignancies, Ready for Prime Time?

Authors:  Andrew D Tieniber; Juanes E Perez; Andrew N Hanna; Ronald P DeMatteo
Journal:  Ann Surg Oncol       Date:  2022-10-22       Impact factor: 4.339
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.